L
Lianbo Yu
Researcher at Ohio State University
Publications - 136
Citations - 7609
Lianbo Yu is an academic researcher from Ohio State University. The author has contributed to research in topics: microRNA & Medicine. The author has an hindex of 33, co-authored 113 publications receiving 5975 citations. Previous affiliations of Lianbo Yu include The Ohio State University Wexner Medical Center.
Papers
More filters
Journal ArticleDOI
The Role of NRG1 in the Predisposition to Papillary Thyroid Carcinoma.
Huiling He,W. G. Li,Sandya Liyanarachchi,Yanqiang Wang,Lianbo Yu,Luke K Genutis,Sophia E. Maharry,John E. Phay,Rulong Shen,Pamela Brock,Albert de la Chapelle +10 more
TL;DR: A role for transcriptional regulation of NRG1 in the predisposition to PTC is suggested, as well as several candidate functional variants harboring differential allelic activities associated with seven SNPs.
Journal ArticleDOI
Stromal PTEN inhibits the expansion of mammary epithelial stem cells through Jagged-1.
Gina M. Sizemore,Subhasree Balakrishnan,Anisha M. Hammer,Katie A. Thies,Anthony J. Trimboli,Julie A. Wallace,Steven T. Sizemore,Raleigh D. Kladney,Sarah Woelke,Lianbo Yu,Soledad Fernandez,Arnab Chakravarti,Gustavo Leone,Michael C. Ostrowski +13 more
TL;DR: A novel stromal PTEN-to-JAGGED-1 axis in maintaining the MaSC niche, and subsequently inhibiting breast cancer initiation and disease progression is unveiled.
Journal ArticleDOI
Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy.
Lorena P. Suarez-Kelly,Amanda Campbell,Isaac Rampersaud,Ambika Bumb,Min S. Wang,Jonathan P. Butchar,Susheela Tridandapani,Lianbo Yu,Arfaan A. Rampersaud,William E. Carson +9 more
TL;DR: Fluorescent nanodiamonds may serve as novel agents with "track and trace" capabilities to stimulate innate immune cell anti-tumor responses, especially as FNDs are amenable to surface-conjugation with immunomodulatory molecules.
Journal ArticleDOI
An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck
Ashley Pinette,Elizabeth L. McMichael,Nicholas B. Courtney,Megan C. Duggan,Brooke Benner,Fouad Choueiry,Lianbo Yu,David Abood,Thomas A. Mace,William E. Carson +9 more
TL;DR: The present data suggest that cetuximab treatment in combination with ALT-803 in patients with EGFR-positive SCCHN may result in significant NK cell activation and have important anti-tumor activity.
Journal ArticleDOI
Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma
Kelly Regan-Fendt,Ding Li,Ryan Reyes,Lianbo Yu,Nissar A. Wani,Peng Hu,Samson T. Jacob,Kalpana Ghoshal,Philip R. O. Payne,Tasneem Motiwala +9 more
TL;DR: This study expedited identification of novel drugs against sorafenib resistant (SR)-HCC and provided proof of concept evidence for validity of this drug repurposing approach for SR-HCC with implications for personalized medicine.